Business Wire

Enterra Unveils EDERS™ to ‘Convert Chaos into Competitive Advantage’

15.4.2025 14:00:00 CEST | Business Wire | Press release

Share

Enterra Solutions launches a groundbreaking new product in response to the unprecedented levels of market instability and uncertainty accelerated by the announcement of reciprocal tariffs and the ensuing global trade war.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415541980/en/

Enterra Solutions – the world’s most advanced complexity sciences company – today announced its Enterra Dynamic Enterprise Resiliency System™ (‘EDERS™’): a groundbreaking new product designed to enable enterprises to convert macroeconomic and geopolitical chaos into powerful competitive advantage.

EDERS™ is built on Enterra’s Autonomous Decision Science Platform®, which enables organizations to autonomously analyze data, predict outcomes, and execute optimized decisions with high accuracy across complex business operations.

It anticipates market shifts and recommends optimal actions and makes decisions with up to 91% accuracy, even in the most volatile economic and political environments.

Stephen DeAngelis, Founder and CEO of Enterra Solutions said:

“EDERS™ is the realization of 24 years’ of academic, government and commercial translational research and successful applications into systemic enterprise resiliency.

“Legacy systems, technologies and processes were built for a time in which seismic economic and geopolitical changes happened every decade, not every month or day. EDERS™ is a fit-for-purpose engineered solution to analyze and control the complex dynamical systems that are the value chains and ecosystems of global corporations and governmental agencies.”

Enterra’s ADS Platform allows EDERS to process vast amounts of internal and external data, anticipating risk to an organization’s most critical assets, as well as those of its competitors. EDERS then systemically predicts and recommends the best actions for the organization to take to avoid or deflect risk, while exploiting market opportunity to win.

“EDERS enables us to put our technology to immediate use today, and deliver insights rapidly to assist our clients with navigating today's, not tomorrow’s, uncertain marketplace,” DeAngelis added. “We can now empower business leaders to quickly understand what levers they can pull and what decisions they can make to turn risk into opportunity in an increasingly volatile global market.”

About Enterra Solutions

Enterra Solutions, founded by Stephen DeAngelis in 2003 and headquartered in Princeton, New Jersey is an advanced data analytics firm that is trusted by large global enterprises such as Nestlé, Hershey’s, General Mills and Kellanova to optimize revenue growth, increase market share, and deliver supply chain efficiencies.

At the core of Enterra’s business is its Autonomous Decision Science (ADS) platform. Unlike traditional analytics or generative AI solutions, Enterra’s ADS uses cutting edge mathematics, multi-modal AI and non-linear optimization to predict future outcomes with up to 91% accuracy.

Enterra ADS® brings together a deep understanding of external market complexities, and siloed and fragmented internal market data, to advise business leaders with unique insights, recommend optimal decisions, and deliver automated execution across value chains using human-like reasoning intelligent agents, with minimal human intervention.

Enterra provides a unified system of intelligence that offers agility in decision-making and builds resilience into the enterprise.

www.enterrasolutions.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250415541980/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye